A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects with Androgenetic Alopecia
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs VDPHL (Primary)
- Indications Male pattern baldness
- Focus Therapeutic Use
- Sponsors Veradermics
- 17 Dec 2024 New trial record